1.
J Med Chem
; 52(4): 1209-13, 2009 Feb 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19161283
RESUMO
New glycolipids and a benzylammonium lipid were rationally designed by varying the chemical structure of a D-glucose-derived hit compound active as lipid A antagonist. We report the synthesis of these compounds, their in vitro activity as lipid A antagonists on HEK cells, and the capacity to inhibit LPS-induced septic shock in vivo. The lack of toxicity and the good in vivo activity suggest the use of some compounds of the panel as hits for antisepsis drug development.